Metal-based antitumor compounds: beyond cisplatin
Metal-based antitumor compounds: beyond cisplatin
About this item
Full title
Author / Creator
Publisher
England: Future Science Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Future Science Ltd
Subjects
More information
Scope and Contents
Contents
Despite improvements in the 5-year survival rate to over 80% in cancers, such as Hodgkin lymphoma and testicular cancer, more aggressive tumors including pancreatic and brain cancer still have extremely low survival rates. The establishment of chemoresistance, responsible for the reduction in treatment efficiency and cancer relapse, is one possible...
Alternative Titles
Full title
Metal-based antitumor compounds: beyond cisplatin
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2179357002
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2179357002
Other Identifiers
ISSN
1756-8919
E-ISSN
1756-8927
DOI
10.4155/fmc-2018-0248
